Hikma Pharmaceuticals Share Discussion Threads

[gertie2shoes] 10/11/2016 09:57

(ShareCast News) - Hikma Pharmaceuticals said on Thursday that it is currently generating "good" revenue growth and expects revenue for the full year to rise by around 35% to $2bn at constant currency.
The injectables division has been performing well in the year to date thanks to investments across its geographies to broaden the company's portfolio and strengthen manufacturing capabilities.

Meanwhile, in the US, good demand across a number of products and new product launches have more than offset increased competition for certain products.

The group said it remains on course to deliver global injectables revenue growth in the mid to high-single digits this year. In addition, thanks to a favourable product mix, it now expects the core operating margin to be around 39%, up from previous guidance of 38%.

Hikma said it has been more challenging than expected since August to generate volume growth in certain products in the generics business. This is expected to continue throughout the rest of the year and the group said full-year revenue in the segment is likely to come in at around $600m.

It still sees full-year core operating profit at between $30m and $40m, reflecting cost savings, including the optimisation of research and development expenses.

In 2017, the enlarged generics business is expected to generate revenue of around $800m.

In the branded division, Hikma has seen a steady improvement in revenue at constant currency in the second half. Due to its focus on higher quality sales and a more challenging environment in the GCC, overall growth has been slightly lower than it was anticipating, however.

The company said the full-year results for the segment on a reported basis will be hit by currency headwinds, which have become more challenging since the recent devaluation of the Egyptian pound.

On a constant currency basis, branded revenue growth is likely to be in the mid-single digits.

Chairman and chief executive Said Darwazah said: "Across the group, we are improving the quality of sales and focusing on profitability. Our global injectables business is delivering good growth and extremely strong margins. In MENA, our focus on strategic products and greater operating efficiencies is helping to absorb strong currency headwinds.

In Generics, the integration of the West-Ward Columbus acquisition is progressing well and we are rapidly implementing cost savings. Although revenue from West-Ward Columbus is ramping up more slowly than originally anticipated, we remain highly confident in the future prospects of the business."

[tsmith2] 10/11/2016 07:32

$40mn miss versus t/o of $2bn, so not really much in scheme of things.Also this is in $ and price has been smashed of late, let's see..

[r ball] 10/11/2016 07:11

Generics miss.

[r ball] 09/11/2016 16:58

Trump and abolishing obamacare.

[tsmith2] 09/11/2016 16:39

trading update tomorrow? I'm litre bit surprised these aren't up more on the day given obamacare is now likely to be shelved..Wait and see but could well motor up

[barriew] 09/11/2016 13:40

I bought in today,as im happy to hold for longer time, as bought my average cost down as over 20£ last purchase,

[sandeep67] 09/11/2016 12:28

£300 loss :(

[mrthomas] 09/11/2016 11:26

Back in again this morning just hope trading update good

[aclark9201] 09/11/2016 09:52

So sandeep67, at 25p a point, just how much did you loose. Please explain how you got out just in time!

[tanners] 09/11/2016 08:30

LOL.....what did you close at?

[sandeep67] 09/11/2016 08:11

Closed just in time

[sandeep67] 08/11/2016 15:21

Come on Hillary. opened second short at £25 a point. You can make me a lot of money tomorrow.

[sandeep67] 08/11/2016 09:42

Well that was a say £540 closed deal now. Opening second sell spread with guaranteed stop @£20 a point. Win done you lose some.

[sandeep67] 08/11/2016 08:52

£25 a point spread bet open on the Sell side. don't let me down

[thaiger] 07/11/2016 22:46

Hima Pharmaceutical not on the list

[sandeep67] 07/11/2016 15:53

Priced in??

[rrb] 07/11/2016 09:10

The reason for the fall last Friday is concern that hikma's subsidiary, west ward, was the first company to hike doxycycline price in 2013 (the year Hikma smashed consensus forecasts driven doxycycline sales).

Price collusion is not good at all. And the comern will be whether they've overpaid for Roxane.

[mrthomas] 06/11/2016 16:36

Thinking of buying in again but have the following few issues to work out
1 trading update on the 10th Thursday
2 US election results out say morning of the 9th unless really tight
3 so could buy in on the 9th the question then at what price I thinking of £15 to 15.5

any views I was 50% up on this share few months ago after holding it only a few months but sold out a week or so ago at 10% gain

Any idea how much is owed by management and can see it losing its TOp 100 spot so that drag the price down as well

[mrthomas] 06/11/2016 16:36

Thinking of buying in again but have the following few issues to work out
1 trading update on the 10th Thursday
2 US election results out say morning of the 9th unless really tight
3 so could buy in on the 9th the question then at what price I thinking of £15 to 15.5

any views I was 50% up on this share few months ago after holding it only a few months but sold out a week or so ago at 10% gain

Any idea how much is owed by management and can see it losing its TOp 100 spot so that drag the price down as well

[sandeep67] 06/11/2016 09:39

Directors must be fuming at the Shareprice. Losing millions on short selling activity. They have lost hundreds of millions on holdings and millions on recent purchases. They own most of the company,but I guess they will not lose faith.I'm down £10k when I bought when they did. Didn't anticipate short selling, Federal intervention into pharma prices and Election sentiment into the prices of drugs. Expecting a good rise into trading statement with a sharp pull back after on same worries.

[broadwood] 04/11/2016 15:44

Numis has upgraded its recommendation on Hikma Pharmaceuticals [LON:HIK] to 'buy' from 'hold' ahead next week's third quarter update and following a 35 per cent decline in the share price over the past three months.

The broker pointed out that the shares have significantly underperformed the UK Mid-Cap Healthcare and Global Specialty Pharma sectors but sees the Q3 results on 10th November and the "Meet the Management" event on 15th November as the catalysts for a re-rating.

Analyst have set a new target price of 2,350 pence per share

[qs99] 04/11/2016 15:18

looks odd IMO....directors been buying in massive size 25% above this price....is it overdone? Am not involved yet, but watching with interest as to when may be a time to dip in!

[tanners] 04/11/2016 09:18

I think this is more than negative sector sentiment ahead of the US election....

[salpara111] 04/11/2016 09:11

Not a holder but had wondered myself as I have them on my watchlist but overall the pharma sector is under the cosh in expectation of a Clinton win as a result I will not be buying any pharma stocks prior to the election. I had Glaxo and sold after the rally which was purely due to £ weakness.